RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC32H47FN6O4S

InChIKeyFRVSRBKUQZKTOW-YOCNBXQISA-N

CAS Registry2169919-21-3

Clinical Trials associated with Revumenib

NCT07052994

/ Not yet recruitingPhase 1IIT

A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients

The goal of Phase 1a of this clinical research study is to find the highest tolerable dose of revumenib that can be given in combination with cytarabine, daunorubicin, and gemtuzumab ozogamicin to patients who have acute leukemia.
The goal of Phase 1b of this clinical research study is to learn if the dose of revumenib in combination with cytarabine, daunorubicin, and gemtuzumab ozogamicin found in Phase 1a can help to control the disease.

Start Date01 Dec 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT07212023

/ Not yet recruitingPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With a KMT2A or NUP98 Gene Rearrangement (REVEAL-ND KMT2A)

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with acute myeloid leukemia (AML) with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy

Start Date01 Dec 2025

Sponsor / Collaborator

Syndax Pharmaceuticals, Inc.

NCT07211958

/ RecruitingPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.

Start Date25 Nov 2025

Sponsor / Collaborator

Syndax Pharmaceuticals, Inc.

100 Clinical Results associated with Revumenib

100 Translational Medicine associated with Revumenib

100 Patents (Medical) associated with Revumenib

Literatures (Medical) associated with Revumenib

01 Dec 2025·ANNALS OF PHARMACOTHERAPY

Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

Review

Author: Faro, Sarah Jane E. ; Lynch, Emilie J. ; Lindstrom, Alec M. ; Sethi, Nadia A. ; Seligson, Nathan D. ; Wang, Wendy Y.

Objective::

To review the pharmacology, efficacy, and safety of revumenib (Revuforj) for relapsed or refractory (r/r) acute leukemia with a lysine methyltransferase 2A ( KMT2A) gene rearrangement or translocation ( KMT2Ar ).

Data Sources::

A literature search was conducted using PubMed/MEDLINE, applicable published abstracts, and ongoing studies from ClinicalTrials.gov between January 1, 1981, and April 23, 2025. Keywords included Revuforj, revumenib, SNDX-5613, KMT2A , MLL1 , and menin.

Study Selection and Data Extraction::

All English-language studies involving revumenib for r/r acute leukemia with a KMT2Ar were included.

Data Synthesis::

Revumenib, a protein-protein inhibitor that interrupts the interaction between the KMT2A protein and the scaffold protein menin, was granted approval by the Food and Drug Administration (FDA) for r/r acute leukemia with KMT2Ar based on a phase 2 clinical trial in adult and pediatric patients (n = 57), which reported a complete remission or complete remission with partial hematologic recovery of 22.8%. Common grade 3/4 adverse reactions reported for revumenib include infectious (febrile neutropenia 33%; infection 29%; bacterial infection 20%) and hematologic events (differentiation syndrome 13%; hemorrhage 9%; thrombosis 5%). Grade 3/4 QT prolongation, the primary dose-limiting adverse effect, was present in 12% of patients. Differentiation syndrome, related to revumenib’s antileukemic effect, was observed in 29% of patients (grade 3/4: 13%; grade 5: <1%). We also include long-term follow-up for a total of 104 and 135 patients for efficacy and safety results, respectively.

Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs::

In the high-risk disease of r/r acute leukemia with KMT2Ar , given limited treatment options, revumenib appears to be a viable, novel treatment option demonstrating clinical efficacy and a manageable adverse effect profile that can be utilized as a bridge to stem cell transplant. Existing therapy options in this setting may include additional traditional chemotherapy, chimeric antigen receptor T-cell therapy (CAR-T), antibody-drug conjugates (eg, gemtuzumab, inotuzumab), bispecific T-cell engager (BiTE) therapies (eg, blinatumomab), DNA methyltransferase inhibitors (eg, azacitidine, decitabine), histone deacetylase inhibitors (eg, vorinostat, panobinostat), and BCL-2 inhibitors (venetoclax).

Conclusions::

Revumenib is an innovative targeted treatment with promising activity in r/r acute leukemia with KMT2Ar .

01 Nov 2025·CURRENT OPINION IN ONCOLOGY

The role of menin inhibitors in acute myeloid leukemia

Review

Author: Marconi, Giovanni ; Isidori, Alessandro

Purpose of review:

Acute myeloid leukemia (AML) characterized by NPM1 mutations or KMT2A rearrangements depends on abnormal epigenetic programs mediated by menin, a critical scaffold protein for sustaining the expression of oncogenic HOX/MEIS1 genes. Therefore, menin inhibitors have become a promising class of AML treatments.

Recent findings:

Early-phase trials have shown that agents such as revumenib, ziftomenib, bleximenib, and enzomenib are active, particularly in relapsed/refractory disease, with 23–48% of patients achieving composite complete remission. However, the durability of single-agent treatment remains limited, and resistance mechanisms, such as MEN1 mutations or transcriptional reprogramming, have been identified. Consequently, combination approaches involving venetoclax, hypomethylating agents, or chemotherapy are being investigated to improve response depth and duration. Recent SAVE, KOMET-007, and cAMeLot-2 trials have demonstrated high overall response rates (68%-100%) and encouraging MRD-negative complete remissions when combining menin inhibitors with venetoclax-based regimens. This has been observed even in patients who have previously received venetoclax. Combinations with intensive chemotherapy (e.g., 7 + 3) in the frontline setting have also yielded high CRc rates (up to 94% in NPM1-mutated AML) without exacerbating toxicity.

Summary:

These findings justify the integration of menin inhibitors into the AML therapeutic landscape, and support ongoing randomized trials to confirm their benefit in both frontline and relapse or refractory settings.

01 Oct 2025·LEUKEMIA RESEARCH

Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapies

Review

Author: Huang, Rui ; Yang, Xinyu

Leukemia driven by rearrangement of the Lysine Methyltransferase 2 A (KMT2A) gene, formerly known as mixed-lineage leukemia (MLL), is associated with poor prognosis due to the formation of oncogenic fusion proteins. Menin, a scaffold protein encoded by the MEN1 gene, plays a critical role in the pathogenesis of KMT2A-rearranged (KMT2A-r) leukemia. Targeting menin has emerged as a promising therapeutic strategy, leading to the development of several menin inhibitors, some of which have entered clinical trials. Notably, Revumenib has been approved for clinical use. However, resistance to menin inhibition is an increasing concern, necessitating alternative approaches. Combining menin inhibitors with other therapeutic strategies appears to enhance efficacy and mitigate resistance. This review summarizes recent advancements in menin inhibitor research for KMT2A-r leukemia, including mechanistic insights and clinical trial progress, while also exploring the potential of combination therapies. A deeper understanding of the mechanisms underlying menin inhibition and resistance is crucial for developing more effective treatments to improve patient outcomes.

181

News (Medical) associated with Revumenib

03 Dec 2025

·www.prnewswire.com

Florida Cancer Specialists & Research Institute Contributing To Breakthroughs In Treatment of Blood Cancers & Disorders

FORT MYERS, Fla., Dec. 3, 2025 /PRNewswire/ -- Results of eleven research studies conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) were selected for presentation at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. The gathering is regarded as the leading global meeting for top researchers and clinicians driving innovation in the treatment of blood cancers and blood disorders. "Our commitment to discovery has yielded significant milestones in advancing the next generation of therapies for blood cancers and other hematologic conditions," said FCS President & Managing Physician Lucio N. Gordan, MD. One of the nation's most extensive community-based oncology research programs, FCS provides access to advanced clinical trials across 29 locations in Florida, including three early-phase drug development units (DDUs). The majority of new cancer drugs approved in recent years for use in the U.S. underwent clinical trials involving FCS participation before gaining approval. FCS was one of the initial two sites involved in the Phase 1 trial of pirtobrutinib, now regarded as a best-in-class targeted therapy for several blood cancers and the first next-generation BTK inhibitor approved by the U.S. Food & Drug Administration (FDA) in 2023 for mantle cell lymphoma (MCL), followed shortly by approvals for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In 2024, the FDA approved revumenib—a revolutionary therapy for relapsed or refractory acute leukemia—after it was first administered to an FCS patient. Manish Patel, MD, FCS Director of Drug Development, has co-authored several abstracts on pirtobrutinib, including two selected for presentation at the ASH annual meeting: Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up Additionally, the following FCS hematologists and medical oncologists are co-authors of abstracts that will be presented in oral or poster presentations: Gustavo Fonseca, MD, FACP, FCS Director of Research & Clinical Trials ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts) Shachar Peles, MD, FCS Director of Cell Therapy Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study Jeffrey Bubis, DO, FACOI, FACP Optimizing processes for adverse event management for bispecific antibodies for diffuse large b-cell lymphoma in community practice: Insights from a quality improvement initiative Jennifer Cultrera, MD Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up Uma Iyer, MD Evaluating the effect of morbid obesity on DVT in patients already on doac therapy: A retrospective analysis Mahender Yellu, MD, MBBS, MHA Nationwide impact of CAR-T approval on acute lymphoblastic leukemia mortality in the United States, 1999-2023: Difference-in-differences and synthetic control analyses Syed Zafar, MD: Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study Functional high-risk relapsed/refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis A comprehensive list of abstracts presented at the 2025 ASH Annual Meeting and Exposition can be found here: ASH Annual Meeting Abstracts. Over 110 new early-phase and 40 late-phase studies are launched annually at FCS in partnership with Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials. Additionally, a partnership with Paradigm Health, Inc. aids in streamlining and accelerating patient matching to available clinical trials. To learn more about clinical trials offered at FCS, visit: About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com) For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program. FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. In fact, before receiving FDA approval, the majority of new cancer drugs in the U.S. were first made available to patients through participation in clinical trials at FCS. Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes. SOURCE Florida Cancer Specialists & Research Institute 21% more press release views with Request a Demo

Phase 2Clinical ResultDrug ApprovalASHPhase 1

14 Nov 2025

·www.pharmaceutical-technology.com

Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy

Kura Oncology and Kyowa Kirin’s Komzifti has gained FDA approval in adult patients with relapsed or refractory acute myeloid leukaemia (r/r AML) with a NPM1 mutation, joining Syndax’s Revuforj as the second menin inhibitor on the AML market. Image credit: Ekahardiwito via Shutterstock.com. Kyowa Kirin’s bet on Kura Oncology appears to have paid off, as the companies have secured approval for their jointly developed drug, Komzifti (ziftomenib). Following the US Food and Drug Administration’s (FDA) call to greenlight the drug, Komzifti will now be available to adult patients with relapsed or refractory acute myeloid leukaemia (r/r AML). The targeted therapy is specifically indicated for patients with a susceptible Nucleophosmin 1 (NPM1) mutation. Komzifti obtained the approval based on the results of the Phase III KOMET-001 study (NCT04067336), which saw the drug trigger complete remission (CR) plus CR with partial haematological recovery (CRh) in 21.4% of patients. This effect was sustained over a median duration of five months. As Komzifti enters the market, it becomes the first once-daily oral menin inhibitor to gain FDA approval in NPM1-mutated r/r AML – an indication with limited treatment options that is commonly associated with poor patient prognoses. It is currently estimated that just under one-third of AML cases present a NPM1 founder mutation. Within this patient population, around 70% of patients will relapse after first-line treatment within three years while 20% do not respond to first-line therapies at all. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Following Komzifti’s approval in this indication, Kura Oncology’s CEO and president Troy Wilson noted that the therapy could become the menin inhibitor of choice within its approved indication due to its “best-in-class profile”. Wilson adds that Kura and Kyowa Kirin are “fully prepared” to launch Komzifti. The pair will also turn their attention to exploring Komzfti’s efficacy in the front-line and combination settings, which could further bolster the drug’s positioning in the AML market. Outside of this indication, Kura is also looking into Komzifti’s potential in treating solid tumours, with the drug having entered the Phase Ia/Ib KOMET-015 trial for gastrointestinal stromal tumours (GIST) in April 2025. Vying for menin inhibitor glory Kyowa Kirin joined forces with Kura in November 2024 to assist with the global development and commercialisation of the drug – setting the company back up to $1.53bn. While Kura will take responsibility for the marketing and manufacturing of Komzifti in the US, Kyowa Kirin will deal with these tasks outside of the US. However, Komzifti will not join the market alone, as less than one month ago, Syndax Pharmaceuticals’ Revuforj (revumenib) got the FDA go-ahead in NPM1-mutated r/r AML. While these drugs exhibited similar efficacy in their respective studies, Revuforj did trigger CR plus CRh in 23% – sitting marginally above Komzifti’s performance in the KOMET-001 study. However, Komzifti does hold a dosing edge over its rival, as it is administered once daily, rather than the twice-daily regimen indicated for Revuforj. Despite this, analysts at GlobalData forecast that Revforj will come out on top sales-wise, becoming a blockbuster seller for Syndax. In 2031, the drug is estimated to pull in $1.1bn for the Massachusetts-based pharma. Meanwhile, analysts predict that Komzifti is set to make $793m for Kura and Kyowa Kirin’s therapy in the same year. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Clinical ResultDrug ApprovalPhase 3

13 Nov 2025

·www.fiercepharma.com

Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval

While specific treatment options for the roughly one-third of AML patients with NPM1 mutations have historically been limited, Syndax Pharmaceuticals broke new ground in late October when the FDA cleared its drug Revuforj as the first menin inhibitor in the indication. Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia.On Thursday, the FDA signed off on Kura’s menin inhibitor ziftomenib as a new treatment for adults with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible nucleophosmin 1 (NPM1) mutation. To qualify for the treatment, which will be marketed under the brand name Komzifti, patients must not be a good fit for any alternative treatments, the FDA said in a Nov. 13 approval announcement.While specific treatment options for the roughly one-third of AML patients with NPM1 mutations have historically been limited, Syndax Pharmaceuticals broke new ground in late October when the FDA cleared its drug Revuforj as the first menin inhibitor in the indication. Syndax’s drug was originally approved last November to treat a genetic type of leukemia called lysine methyltransferase 2A (KMT2A).The two meds, both members of the same class, will now likely compete directly over the indication.NPM1 mutations rank among the most common founder mutations in AML, Kura and Kyowa Kirin said in a joint press release Thursday. Roughly 20% of patients with NPM1-m AML do not respond to frontline therapy, and of those who do, some 70% will relapse within three years, according to the partners. The FDA granted its green light after reviewing data from the partners’ pivotal KOMET-001 trial, in which 21.4% patients on Komzifti achieved complete remission (CR) or CR with partial hematologic recovery (CRh), Kura and Kyowa Kirin said in their release. The median duration of remission among those who achieved CR or CRh clocked in at 5 months, the partners said. Further, 88% of patients who hit either CR or CRh did so within half a year of starting treatment with Komzifti, Kura and Kyowa Kirin added.Komzifti will carry a boxed warning for differentiation syndrome—a potentially severe reaction to certain leukemia treatments—though patients and doctors applying more scrutiny to which drugs they prescribe alongside Komzifti can ease those potential risks, according to the companies’ approval announcement. The drug also bears precautions around QTc interval prolongation and embryo-fetal toxicity.Syndax’s Revuforj label bears similar warnings and precautions, with its boxed warnings discussing risks of differentiation syndrome, QTc prolongation and the fast heart rhythm condition Torsades de Pointes.The safety profile of Kura and Kyowa's drug "overall looks a bit better" than that for Revuforj, analysts at Mizuho Securities concluded, adding that a differentiation syndrome boxed warning for the menin inhibitor class comes as "[n]o real surprise." “Komzifti combines compelling efficacy, a favorable safety profile, compatibility with concomitant medications, and convenient once-daily oral administration in a population with few effective treatment options,” Troy Wilson, Ph.D., CEO of Kura, said in a statement. “These features highlight Komzifti’s potential to serve as the menin inhibitor of choice in its approved indication.”Kyowa Kirin hitched its wagon to Kura and ziftomenib just shy of a year ago, paying $330 million upfront in November 2024—and pledging up to $1.1 billion in potential milestones—to split development and commercialization on the asset.Under the deal, Kura is in charge of development, regulatory and commercial strategy for Komzifti in the U.S., as well as manufacturing, while Kyowa Kirin is holding down R&D and marketing duties outside the U.S. In their press release, the partners said that following the approval, they will now “jointly perform certain commercialization activities in accordance with a co-created U.S. territory commercialization plan.”Kura’s stock was trading up around 1% on Thursday morning. Editor's note: This story was updated to clarify information on Komzifti's label, and to include analyst commentary.

Drug ApprovalClinical ResultClinical Study

100 Deals associated with Revumenib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute myeloid leukemia with mutated NPM1	United States	Syndax Pharmaceuticals, Inc.	24 Oct 2025
Acute Leukemia with a KMT2A Translocation	United States	Syndax Pharmaceuticals, Inc.	15 Nov 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colorectal Cancer	Phase 2	United States	Syndax Pharmaceuticals, Inc.	04 Apr 2023
Acute Lymphoblastic Leukemia	Phase 2	United States	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	Australia	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	Canada	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	France	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	Germany	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	Israel	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	Italy	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	Lithuania	Syndax Pharmaceuticals, Inc.	05 Nov 2019
Acute Lymphoblastic Leukemia	Phase 2	Netherlands	Syndax Pharmaceuticals, Inc.	05 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04065399 (AUGMENT-101, EHA2025)	Phase 1	acute leukemia NUP98r	34	Revumenib	tbdtyoqlry(eiyryzcnmk) = oqvcziywxt sgnzhyqkrg (sdsdyrrsxp ) View more	Positive	14 May 2025
NCT04065399 (AUGMENT-101, EHA2025)	Phase 2	acute leukemia	116	Revumenib 163 mg	arvybctjba(mmuyvsvvde) = ishsircukf eoybqaognz (nyrenmjfkf, 54 - 73) View more	Positive	14 May 2025
NCT04065399 (AUGMENT-101, EHA2025)	Phase 2	Acute myeloid leukemia with mutated NPM1	84	Revumenib 160 mg	trefqxjgag(wprhxphgfy) = geayxnqlnz fyfutobhtp (olkthhioyc, 36.5% - 59.7) View more	Positive	14 May 2025
NCT04065399 (AUGMENT-101, Company_Website \| Pubmed) Manual	Phase 2	Acute myeloid leukemia with mutated NPM1 NPM1 Mutation	84	Revumenib	qetepfmbxa(ghavommpku) = vkvsqwpcpe svxoafpvdm (jjdboljxhd, 14 - 36) View more	Positive	07 May 2025
NCT04065399 (AUGMENT-101, ASH2024 \| Company_Website) Manual	Phase 2	acute leukemia KMT2A Rearrangement	116	Revumenib 163 mg	mwlvuutztq(lwvtpadurd) = lkfslmeidh iddamfwbvh (zseznbgflx, 15 - 32) View more	Positive	07 Dec 2024
NCT05360160 (ASH2024) Manual	Phase 1/2	Acute Myeloid Leukemia NPM1 Mutation \| KMT2A Rearrangement \| NUP98 Rearrangement	26	Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE)	nnpppsbhem(hrthkeeotk) = hjxqobnwqd apatvddxjn (bsicvoagqy ) View more	Positive	07 Dec 2024
NCT04065399 (AUGMENT-101 \| SNDX-5613-0700, FDA_CDER) Manual	Phase 1/2	Acute Leukemia with a KMT2A Translocation 11q23 partial tandem duplication	104	REVUFORJ	snisvicwqy(omptibophe) = jwibrpbwox ziikrmpfcx (qoswmkeaso, 13.8 - 30.3) View more	Positive	15 Nov 2024
NCT04065399 (AUGMENT-101, Pubmed \| J Clin Oncol) Manual	Phase 1/2	Acute myeloid leukaemia with 11q23 abnormality	94	Revumenib 163 mg (95 mg/m2 if weight <40 kg)	gyvgkcclfo(ekdapymazm) = ydgqaahcax xqtpfidoer (hhkcktyrpe, 12.7 - 35.8) View more	Positive	09 Aug 2024
NCT04065399 (AUGMENT-101, EHA 12024 \| EHA 22024) Manual	Phase 2	Acute myeloid leukaemia with 11q23 abnormality First line KMT2A Rearrangement	94	Revumenib 163 mg	ttqtnizpob(pqcrsiqago) = ltracvtmtz ibpaojvdwl (curxcdorjt, 12.7 - 35.8) View more	Positive	14 May 2024
NCT05326516 (EHA2024)	Phase 1	Leukemia	27	Revumenib + FLA DL1	fyvfrjuury(agiumwfwjt) = occurred in >50% of pts pkvlrzgguv (jlkvptzhom ) View more	Positive	14 May 2024
NCT05326516 (EHA2024)	Phase 1	Leukemia	27	Revumenib + FLA DL2		Positive	14 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Revumenib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation